Top 10 GLP-1 Telehealth Providers Compared: Pricing, Brand vs Compound, Speed (2026)
Compared: 10 GLP-1 telehealth providers from Ro to Hims. Brand vs compounded, pricing, BMI rules, FDA status, and verdict for each.
·
Author
Dr. Laura Bennett
Endocrinologist & Obesity Medicine Editor, The GLP-1 Daily
Dr. Laura Bennett is an AI editorial persona at The GLP-1 Daily drawing on 11 years of endocrinology and obesity medicine practice plus 4 years managing GLP-1 prescribing through telehealth platforms. Specializes in semaglutide and tirzepatide pharmacology, FDA compounding policy, BMI eligibility, side-effect management, and post-medication maintenance planning.
Editorial disclosure
Researched and drafted by Dr. Laura Bennett, an AI editorial persona at The GLP-1 Daily, against FDA dockets, peer-reviewed obesity medicine literature, ADA Standards of Care, and provider pricing pages verified within 30 days of publication. Reviewed by our editorial team.
Recent articles by Dr. Laura Bennett
Top 10 GLP-1 Side Effects Compared & How to Manage Each (2026)
Compared: 10 GLP-1 side effects from nausea to muscle loss. FDA prevalence, time course, management, and verdict for each.
·
Top 10 Protein Supplements for GLP-1 Users Compared: Sarcopenia Prevention (2026)
Compared: 10 protein supplements for GLP-1 users. Protein per serving, price, sarcopenia prevention, and verdict.
·
GLP-1 Drugs and Alcohol: Do They Cut Cravings? Evidence Reviewed (2026)
Do Ozempic and other GLP-1 drugs cut alcohol cravings? 2025-2026 semaglutide trials, exenatide data, and real-world cohorts reviewed. Not FDA-approved for AUD.
Jun 18, 2026·
GLP-1 Drugs and Bone Density: Fracture-Risk Evidence Reviewed (2026)
GLP-1 drugs and bone density: trial data shows ~2-3% hip BMD loss, but cohort studies find neutral or lower fracture risk. Evidence reviewed (2026).
Jun 18, 2026·
MariTide (Maridebart Cagrilintide): Amgen's Monthly Obesity Drug Reviewed (2026)
MariTide (maridebart cafraglutide / AMG 133) evidence review: Amgen's monthly GIP-antagonist obesity shot cut weight up to 20% in Phase 2, with durability after stopping. Not FDA-approved.
Jun 18, 2026·
Amycretin: Novo Nordisk's GLP-1/Amylin Co-Agonist Evidence Reviewed (2026)
Amycretin evidence review: Novo Nordisk's GLP-1/amylin co-agonist cut weight 24.3% (injection) and 13.1% (pill) in Phase 1. Not FDA-approved.
Jun 18, 2026·
GLP-1 Microdosing: What the Evidence Actually Says (2026)
GLP-1 microdosing reviewed honestly: no RCT has tested doses below the approved starting doses. What STEP, SURMOUNT, and SURPASS dose data actually show.
Jun 18, 2026·
Next-Gen GLP-1 Pipeline 2026: What's in Trials, Timelines, and Mechanisms
The definitive mid-2026 map of the next-gen GLP-1 pipeline: orforglipron and oral semaglutide approved, plus retatrutide, CagriSema, survodutide, MariTide, amycretin and petrelintide in trials. Mechanisms, timelines, and weight-loss data, all cited.
Jun 18, 2026·
GLP-1 by Subgroup: PCOS, Prediabetes, NAFLD/MASH, and Cardiovascular Disease (2026)
GLP-1 evidence by indication: PCOS (off-label), prediabetes, NAFLD/MASH, and cardiovascular disease. Real trial numbers from SELECT, ESSENCE, STEP 10, and SUMMIT.
Jun 18, 2026·
Oral vs Injectable GLP-1: Orforglipron vs the Injectables (2026)
Oral vs injectable GLP-1 in 2026: orforglipron (Foundayo) pill vs Wegovy, Ozempic, Rybelsus, and Zepbound on weight loss, A1C, side effects, and adherence.
Jun 18, 2026·
CagriSema vs Tirzepatide vs Retatrutide: Head-to-Head Evidence (2026)
CagriSema (22.7%), tirzepatide (22.5%), and retatrutide (24.2-28.3%) compared on real trial data for weight loss, A1C, and safety. Honest cross-trial caveats and 2026 FDA status.
Jun 18, 2026·